Metric Finance
LearnFAQ
LearnFAQ

Learn / LXRX

NASDAQ: LXRX

Lexicon Pharmaceuticals (LXRX) stock, explained like you're 5

Lexicon Pharmaceuticals trades on the Nasdaq under the ticker LXRX. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 748 million dollars.

Ticker
LXRX
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceutical Preparations
Size
Small cap, about 748 million dollars

Is Lexicon Pharmaceuticals a small, medium or large cap company?

No. Lexicon Pharmaceuticals is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 748 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Lexicon Pharmaceuticals makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves LXRX stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress (Yahoo Finance)
  • Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today (The Motley Fool)
  • Lexicon Pharmaceuticals (NasdaqCM:LXRX) Stock Forecast & Analyst Predictions (Simply Wall Street)
  • LXRX Stock Edges Higher On $10M Payout From Novo Nordisk Retail Traders Highlight More Cash Milestones On The Horizon (Stocktwits)
  • Why is Lexicon Pharmaceuticals stock surging today? (Investing.com)

Follow LXRX in your daily brief

Each trading day at 5 PM ET we post what happened to Lexicon Pharmaceuticals and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow LXRX

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Lexicon Pharmaceuticals stock

What does Lexicon Pharmaceuticals do?

Lexicon Pharmaceuticals trades on the Nasdaq under the ticker LXRX. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 748 million dollars.

What is the ticker symbol for Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals trades under the ticker LXRX on the Nasdaq.

What is Lexicon Pharmaceuticals's market cap?

Lexicon Pharmaceuticals is a small cap stock with a market cap of about 748 million dollars.

How does Lexicon Pharmaceuticals make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves LXRX stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow LXRX stock every day?

Add LXRX to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow LXRX daily

A free brief on Lexicon Pharmaceuticals and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • NVS · Novartis AG
  • AZN · Astrazeneca PLC
  • NVO · Novo Nordisk A S
  • VRTX · Vertex Pharmaceuticals Inc / Ma

Similar stocks

  • NVSNovartis AG
  • AZNAstrazeneca PLC
  • NVONovo Nordisk A S
  • VRTXVertex Pharmaceuticals Inc / Ma

Compare LXRX: LXRX vs NVS, LXRX vs AZN, LXRX vs NVO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed